NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.757
-0.002 (-0.21%)
At close: Jun 26, 2026, 4:00 PM EDT
0.759
+0.002 (0.21%)
After-hours: Jun 26, 2026, 6:47 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
26.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Evaxion | 46 |
| Vistagen Therapeutics | 41 |
| Kyntra Bio | 34 |
| Plus Therapeutics | 28 |
| Tevogen Bio Holdings | 18 |
| BriaCell Therapeutics | 16 |
| Serina Therapeutics | 16 |
NRSN News
- 3 days ago - NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PRNewsWire
- 6 days ago - EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots - PRNewsWire
- 17 days ago - NeuroSense granted South Korean patent covering PrimeC composition for ALS - TheFly
- 17 days ago - NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - PRNewsWire
- 19 days ago - NeuroSense granted Japanese patent for PrimeC novel composition in ALS - TheFly
- 19 days ago - NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition - PRNewsWire
- 7 weeks ago - NeuroSense Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - NeuroSense Announces Pricing of Insider-Led PIPE Financing - PRNewsWire